compound introduction
GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC 50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC 50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus ( HCV ) research Form:Solid IC50& Target:PI4KA 8.5-9.8 (pIC 50 ) PI4KB 7.2-7.7 (pIC 50 ) PI4K2A
